Cytognos

Cytognos is a private, revenue-generating diagnostics company with over two decades of experience in the flow cytometry market. The company's core strategy involves licensing and commercializing innovative technologies from academic consortia, most notably the EuroFlow™ consortium, to address gaps in multicolor flow cytometry workflows. Its flagship offerings include the Next Generation Flow™ standardized testing approach and the Infinicyt™ software, targeting improved diagnosis and monitoring of hematological malignancies and immunodeficiencies. Cytognos maintains ISO 13485 and ISO 9001 certifications, underscoring its commitment to quality in the medical device and diagnostic sectors.

Next Generation Flow™ (NGF) standardized flow cytometry platform, developed with the EuroFlow™ consortium. Includes standardized reagent kits, protocols, and Infinicyt™ data analysis software for high-sensitivity, reproducible cell analysis in diagnostics and research.

Cytognos competes in the flow cytometry reagent and software market against large, established players like Becton Dickinson (BD), Beckman Coulter, and Bio-Rad. Its differentiation lies in its specialized, standardized kits and protocols developed with the EuroFlow consortium, targeting specific high-value clinical niches in hematology and immunology where standardization is a critical unmet need.